Bank of Montreal Can grew its stake in The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 51.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 326,520 shares of the medical device company’s stock after buying an additional 110,878 shares during the period. Bank of Montreal Can owned approximately 0.16% of Cooper Companies worth $35,845,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Innealta Capital LLC bought a new stake in shares of Cooper Companies in the 2nd quarter worth approximately $25,000. Ashton Thomas Securities LLC purchased a new stake in shares of Cooper Companies in the 3rd quarter worth about $25,000. Crewe Advisors LLC grew its position in shares of Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the period. Tortoise Investment Management LLC grew its position in shares of Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after buying an additional 169 shares during the period. Finally, Covestor Ltd grew its position in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 24.39% of the company’s stock.
Insider Transactions at Cooper Companies
In related news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares in the company, valued at approximately $18,267,624.69. The trade was a 41.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian G. Andrews sold 24,788 shares of the business’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. This represents a 78.94 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Cooper Companies
Cooper Companies Price Performance
Shares of NASDAQ:COO opened at $103.43 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. The Cooper Companies, Inc. has a 1-year low of $82.21 and a 1-year high of $112.38. The company has a market capitalization of $20.60 billion, a P/E ratio of 57.46, a P/E/G ratio of 2.21 and a beta of 0.99. The firm’s 50 day simple moving average is $105.45 and its two-hundred day simple moving average is $98.48.
Cooper Companies (NASDAQ:COO – Get Free Report) last released its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same quarter in the previous year, the firm earned $0.84 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Research analysts expect that The Cooper Companies, Inc. will post 3.65 EPS for the current fiscal year.
Cooper Companies Profile
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.
Further Reading
- Five stocks we like better than Cooper Companies
- What is a buyback in stocks? A comprehensive guide for investors
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Find and Profitably Trade Stocks at 52-Week Lows
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- 3 Healthcare Dividend Stocks to Buy
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.